CTICasesLung Adenocarcinoma with Targeted Therapy Response
Imaging findings
Progressive lymphangitic carcinomatosis and pleural effusion despite platinum-based therapy. Dramatic improvement observed after initiating targeted therapy.
Key takeaways
Identifying specific driver mutations (e.g., ERBB2/HER2) allows for targeted therapies that can lead to significant clinical and radiographic improvement in stage IV lung cancer.
AI-assisted summary — may contain errors. Verify against the source video. Learn more
More from this webinar
- Granulomatosis with Polyangiitis (GPA) with Splenic InvolvementAutoimmune
- Alpha-1 Antitrypsin DeficiencyCongenital
- Severe Chronic SarcoidosisAutoimmune
- Minimal Aortic InjuryTrauma
- Thymic Carcinoid and MEN1 SyndromeNeoplastic
- AICD Lead MigrationIatrogenic
- Humeral Internal Fixation with Light-Activated SystemArtifact
- Empyema NecessitansInfection
See all cases from February 1, 2024 →